• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners

    5/28/26 12:00:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email

    From connected fitness and cycle tracking to meal delivery and glucose monitoring, Hims & Hers subscribers now have ten ways to support their whole-body health

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers Benefits, adding eight new partners to the Hims & Hers exclusive program. Joining founding partners Prenuvo and Eight Sleep are Natural Cycles, MyFitnessPal, Ladder, PVOLVE Studios, HelloFresh, Factor, Flo Health, Dexcom, and iFIT - a carefully curated lineup spanning nutrition, fitness, women's health, metabolic monitoring, and connected wellness.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528501192/en/

    Together, the program now offers subscribers 10 ways to access the tools and innovations that support whole-body health, all in one place. The expansion reflects Hims & Hers' ongoing commitment to investing in the subscription experience, ensuring that Hims & Hers delivers meaningful value well beyond the personalized treatment plans available through the platform.

    "Healthcare is most powerful when your treatment, your data, your nutrition, and your fitness all work together toward the same goal," said Dheerja Kaur, Chief Product Officer at Hims & Hers. "Hims & Hers Benefits are an expression of that belief. By pairing clinical expertise and personalized treatment plans with access to best-in-class health and wellness tools, we're creating a membership experience that goes beyond traditional care — one that supports every dimension of whole-body health, seamlessly, in one place."

    Hims & Hers Benefits will continue to grow, with plans to add new partners across every dimension of whole-body health. The program now features ten leading brands spanning nutrition, fitness, women's health, metabolic monitoring, and connected wellness. Today's new Benefits include:

    • AI coaching that maximizes GLP-1 results with iFIT. Exercise is a powerful complement to GLP-1 treatment — and iFIT makes it personal. Its AI-powered coaching adapts to your fitness data, building science-backed workouts around your specific goals so you can see results faster and build habits that last. Subscribers can get their first three months free ($59.97 value).
    • Build real strength with Ladder. Ladder takes the guesswork out of fitness with expert-programmed strength workouts, built-in progress and nutrition tracking, and coaching that evolves as you do, all in one app. Subscribers receive the first three months free (an $89.97 value).
    • Track food, exercise, and calories with MyFitnessPal. Understanding what you eat is one of the most powerful tools for lasting change. MyFitnessPal makes it effortless with fast logging AI tools, customized meal plans, exercise tracking, and weight all in one place. Hims & Hers subscribers can receive 15% off the annual Premium+ subscription.
    • Eat better, without the effort, with HelloFresh. Healthy eating starts with what's in your kitchen. HelloFresh delivers chef-designed recipes and fresh, pre-portioned ingredients straight to your door, making it easier to cook well even on your busiest nights. Subscribers receive eleven free meals.
    • Nourish your body with Factor. When time is tight but nutrition matters, Factor delivers fresh, never frozen meals that are ready to eat in minutes — no prep, no compromise. Built on real, whole ingredients and free of refined sugars, seed oils, and artificial sweeteners, every dietitian-designed Factor meal is as nutritious as it is convenient. Subscribers can receive 50% off their first box plus free breakfast items for a full year.
    • Track your periods, ovulation, pregnancy, perimenopause and more with Flo Health. Flo transforms health data into personalized, clinical-grade insights, tracking a woman's cycle, ovulation, and hormonal patterns through every stage of her life with the kind of nuance that adapts as their body changes. It's the #1 women's health app in the world. Subscribers can receive 40% off their subscription.
    • Take control of your reproductive health with Natural Cycles°. The only FDA-cleared women's health app powerful enough to prevent pregnancy, Natural Cycles uses body temperature data to deliver personalized, clinically validated insights across every phase of a woman's cycle. Subscribers can receive 28 days of complimentary access to the NC° app, with the flexibility to connect an existing compatible wearable or use the included NC° Band.
    • Move better, for longer, with PVOLVE Studios. Built on a method that uniquely combines the three pillars of longevity training: strength, mobility, and stability. Using patented resistance equipment and functional movement patterns, PVOLVE sculpts and tones the body, while building deeper mind-body awareness helping members move better, longer. Subscribers can receive discounts on in-studio classes.
    • Stelo by Dexcom, is a small, wearable glucose biosensor worn on the back of the upper arm. Designed for adults 18 and older not using insulin, Stelo is the first FDA-cleared glucose biosensor available without a prescription in the U.S. Built on Dexcom's most accurate glucose sensing technology,1 Stelo gives you real-time insight into how food, movement, stress, and sleep affect your glucose, helping you make smarter, more informed decisions every day. Stelo is available as part of Hims & Hers Benefits for eligible subscribers. Sign in for member benefit details.
    ____________________

    1

    Dexcom, Data on file, 2024 2 Stelo, User Guide, 2024

    Underpinning the company's commitment to put its customers first, Hims & Hers does not profit from these benefits. Instead, 100% of the negotiated benefits are passed directly to active subscribers.

    *See full terms and conditions at hims.com/benefits and forhers.com/benefits. Active Hims & Hers subscribers can access these benefits immediately.

    Stelo Safety Information: For full information on risks and benefits, visit stelo.com.

    About Hims & Hers Health, Inc

    Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260528501192/en/

    Press Contact

    Susan Cadrecha

    press@forhims.com

    Get the next $HIMS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    5/12/2026$30.00 → $35.00Buy
    Needham
    4/24/2026$35.00Overweight
    Analyst
    3/10/2026$24.00Sell → Neutral
    Citigroup
    3/10/2026$23.00Underperform → Neutral
    BofA Securities
    3/9/2026$30.00Hold → Buy
    Needham
    2/24/2026Buy → Neutral
    BTIG Research
    1/12/2026$33.00In-line
    Evercore ISI
    12/9/2025$48.00Overweight
    Barclays
    More analyst ratings

    $HIMS
    SEC Filings

    View All

    Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    6/2/26 6:02:26 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    5/21/26 5:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health Inc. filed SEC Form 8-K: Other Events

    8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

    5/19/26 8:17:31 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hims & Hers Completes Acquisition of Eucalyptus, Accelerating Its Push to Transform Healthcare for Canadians

    Building on its Canadian launch and the historic introduction of generic semaglutide, Hims & Hers brings the full power of the world's largest consumer health platform — and Juniper's proven track record — to more Canadians than ever Hims & Hers Health, Inc. today announced the completion of its acquisition of Eucalyptus, the parent company of Juniper, marking the latest in a series of significant company investments in Canada. Since launching in 2025, Hims & Hers has already changed the game in Canada, becoming the first platform to bring generic semaglutide to eligible Canadians. By combining Juniper's proven platform with the technology, data, and clinical infrastructure that has advan

    6/2/26 5:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Completes Acquisition of Eucalyptus, Expanding Access to Comprehensive, Clinically-Backed Weight Management Care in Germany

    Closing brings world-class technology and clinical infrastructure to a market where Juniper has helped patients achieve clinically meaningful weight loss Hims & Hers Health, Inc. has completed its acquisition of Eucalyptus, the parent company of Juniper, advancing its position as the world's largest consumer health platform. In Germany, the closing strengthens Juniper's comprehensive, clinically rigorous, weight management offering with the technology, data, and infrastructure of Hims & Hers behind it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602926942/en/Closing brings world-class technology and clinical infrastructu

    6/2/26 5:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World's Largest Consumer Health Platform

    The acquisition extends the company's leadership position across Australia, Canada, Germany, Japan, and the United Kingdom, with the scale to redefine healthcare for hundreds of millions of people Hims & Hers Health, Inc. (NYSE:HIMS) has completed its acquisition of Eucalyptus, advancing its position as the world's largest consumer health platform. Building on the earlier acquisitions of ZAVA and Livewell, Hims & Hers now has a leading presence across the US, UK, Australian, and Canadian markets, with a growing presence in France, Germany, Ireland, Spain, and Japan. Continuing to expand internationally will enable Hims & Hers to lead the next era of digital health, delivering personal, af

    6/2/26 5:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wells David B bought $1,172,974 worth of shares (48,400 units at $24.23), increasing direct ownership by 27% to 224,417 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/26/26 4:48:28 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chief Medical Officer Carroll Patrick Harrison

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/26 4:16:21 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Director Wells David B

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/26 4:16:05 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Hims & Hers Health with a new price target

    Needham reiterated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $35.00 from $30.00 previously

    5/12/26 10:08:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Analyst initiated coverage on Hims & Hers Health with a new price target

    Analyst initiated coverage of Hims & Hers Health with a rating of Overweight and set a new price target of $35.00

    4/24/26 8:05:39 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health upgraded by Citigroup with a new price target

    Citigroup upgraded Hims & Hers Health from Sell to Neutral and set a new price target of $24.00

    3/10/26 8:37:35 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wells David B bought $1,172,974 worth of shares (48,400 units at $24.23), increasing direct ownership by 27% to 224,417 units (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/26/26 4:48:28 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    11/14/24 4:57:45 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

    4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

    5/22/24 4:16:26 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Nominates Kofi Amoo-Gottfried to its Board of Directors

    If elected, the marketing leader from transformative companies like DoorDash and Meta will join a diverse board with medical, tech, and consumer expertise Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, has nominated Kofi Amoo-Gottfried for election as a new director at the company's 2026 annual shareholder meeting in June. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428343333/en/If elected, the marketing leader from transformative companies like DoorDash and Meta will join a diverse board with medical, tech, and consumer expertise. Amoo-Gottfried is a seasoned marketing l

    4/28/26 8:35:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Names Kathryn Beiser as Chief Communications Officer

    The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world's leading consumer health platform in its next phase of growth Hims & Hers Health, Inc. (NYSE:HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and internal communications for the company as it enters a new phase of domestic and international growth. In her role as CCO, Beiser will report to CEO Andrew Dudum and focus on continuing to build the Hims & Hers brand and reputation while helping the industry understand the company's expansive vision for the

    3/10/26 8:08:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/12/24 3:52:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 1:33:02 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

    SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

    11/4/24 12:09:24 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $HIMS
    Financials

    Live finance-specific insights

    View All

    Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results

    Revenue of approximately $608 million, up 4% year-over-year in Q1 2026 Subscribers grew to nearly 2.6 million, up 9% year-over-year in Q1 2026 Raises full year 2026 revenue guidance1 to a range of $2.8 billion to $3.0 billion and updates Adjusted EBITDA guidance to a range of $275 million to $350 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2026. Moving forward, the Company plans to transition to an annual rather than quarterly shareholder letter and will continue to provide regular updates through a quarterly earnings call, earnings rele

    5/11/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026

    Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report first quarter 2026 financial results after the market closes on Monday, May 11, 2026. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's management

    4/13/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 billion and Adjusted EBITDA in the range of $300 million to $375 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2025 in a shareholder letter that is posted at investors.hims.com. "More than 2.5 million subscribe

    2/23/26 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care